Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician

Supply bottlenecks linked to centralized distribution are slowing the pace at which patients are switching to GlaxoSmithKline’s long-acting HIV injectable Cabenuva, according to a U.S.-based expert clinician.